kailera.com 的前十大競爭對手

nanobiotix.com

Laurent Lévy is the Cofounder of Nanobiotix and has served as Chief Executive Officer since 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in the sciences and techniques related to nanotechnology. Prior to founding Nanobiotix, Laurent served as a consultant for Altran Technologies and worked in the development of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., Rhodia S.A., and other early-stage biotechnology companies. He served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL), was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN), and was a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN). Laurent has authored more than 35 scientific publications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a doctorate in physical chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA), and a DEA (advanced studies and diplomas) in physics of condensed matter from the UPVI-ESPCI. Laurent completed his studies with a postdoctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo).

alector.com

All candidate activity and open positions are managed strictly through our Talent Acquisition department.

tectonictx.com

Tectonic is a biotechnology company focused on the discovery and development of proteins and antibodies that modulate the activity of G-Protein Coupled Receptors.

viridiantherapeutics.com

WALTHAM, Mass.–(BUSINESS WIRE)– Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering,Read More

bbotx.com

Taking Precision Oncology to New Heights. Get in touch with us. Are you interested in joining our team, learning more or partnering with us?

biopharmadive.com

The latest pharma news for biotech and biopharmaceutical professionals

fiercebiotech.com

|

pharmaphorum.com

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna. Jameka talks about her own passion for and experience with health equity and population health, then casts her eye back to the height of the pandemic, when Moderna was in a race against time – and several other pharma companies – to develop a vaccine for COVID-19.

biospace.com

Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs. The news comes less than a week after the president announced up to 100% levies on pharma products.